SCHEMBL30748731

SCHEMBL30748731

CC1(C)CN(c2ccc(N3CCOCC3)cc2)c2nc(CO)nc(NCc3ccccc3)c21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CB P42338 5/20 0.45
PIK3CA P42336 1/20 0.45
PLK4 O00444 2/20 0.44
PDE5A O76074 1/20 0.44
HTT P42858 2/20 0.43
STAT6 P42226 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
PKM P14618 2/20 0.41
TSHR P16473 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
LMNA P02545 2/20 0.40
ACHE P22303 1/20 0.40
USP1 O94782 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31691490 0.85 PLK4 (0.40) PIK3CBPIK3CAPLK4PDE5AHTT
SCHEMBL30748757 0.81 ALDH1A1 (0.41) HTTALDH1A1KDM4ETSHRLMNA
SCHEMBL30749134 0.74 LRRK2 (0.43) PIK3CA
SCHEMBL30749056 0.74 TTK (0.43) PIK3CAALDH1A1
SCHEMBL30748758 0.73 APP (0.37)
SCHEMBL30749038 0.71 ADORA3 (0.39) PIK3CBPIK3CAHTTSTAT6L3MBTL1
SCHEMBL30748952 0.70 SYK (0.37) L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL30748787 0.69 L3MBTL1 (0.36) PIK3CBPIK3CAHTTL3MBTL1ALDH1A1
SCHEMBL30749122 0.68 TNK2 (0.36) L3MBTL1KDM4E
SCHEMBL30749053 0.67 ALDH1A1 (0.48) PIK3CBPIK3CAHTTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT PIK3CB 3181/4885PIK3CA 1906/4885PLK4 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.